Full Text View
Tabular View
No Study Results Posted
Related Studies
Neurobiology of Opioid Dependence: 2 - 2
This study has been completed.
Study NCT00000193   Information provided by National Institute on Drug Abuse (NIDA)
First Received: September 20, 1999   Last Updated: June 23, 2005   History of Changes

September 20, 1999
June 23, 2005
January 1996
 
  • Behavioral, subjective, measures of naloxone-preci
  • Phsyiological, neuroendocrine measures of naloxone
Same as current
Complete list of historical versions of study NCT00000193 on ClinicalTrials.gov Archive Site
 
 
 
Neurobiology of Opioid Dependence: 2 - 2
Neurobiology of Opioid Dependence: 2

The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.

 
Phase II
Interventional
Treatment, Double-Blind, Placebo Control
Opioid-Related Disorders
Drug: Gamma hydroxybutyric
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
0
 
 

Please contact site for information.

Male
 
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00000193
 
NIDA-00191-2, K20-00191-2
National Institute on Drug Abuse (NIDA)
Yale University
Principal Investigator: Marc I Rosen, M.D. VA Connecticut Healthcare System
National Institute on Drug Abuse (NIDA)
October 1996

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP